ISSN 2305-3127 (Print)   
ISSN 2664-3790 (Online)

 

TAVI: past, present and future. On the 20th anniversary of the world’s first endovascular aortic valve implant

M.V. Stan, A.V. Khokhlov, O. V. Zelenchuk, B.M. Todurov, N.V. Ponych, M.B. Todurov, Kh.M. Monastyrska, M.Ya. Slyubyk, Ya.A. Antoniuk

References

  1. ACC Annual Scientific Session, ACC22. CoreValve US Pivotal and SURTAVI Trials Show Rate of SVD Lower With TAVR Than With SAVR. Apr 04, 2022.
  2. Ali N, Faour A, Rawlins J, et al. «Valve for Life»: tackling the deficit in transcatheter treatment of heart valve disease in the UK. Open Heart. 2021;8:e001547. doi:10.1136/ openhrt-2020-001547.
  3. Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59:178. doi:10.1016/j.jacc.2011.09.061.
  4. Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017;70:42–55. doi:10.1016/j.jacc.2017.04.053.
  5. Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673–84. doi:10.1016/j.jacc.2016.05.065.
  6. Baumgartner H, Falk V, Bax JJ, De Bonis M, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91. doi:10.5603/KP.2018.0013
  7. Bourguignon T, Bouquiaux-Stablo A-L, Candolfi P, Mirza A, et al. Very long-term outcomes of the carpentier-edwards perimount valve in aortic position. Ann Thorac Surg. 2015;99:831–7. doi:10.1016/j.athoracsur.2014.09.030.
  8. Brouwer J MD, Nijenhuis VJ MD, Delewi R MD, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;383:1447–57. DOI:10.1056/NEJMoa2017815.
  9. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017;69:325–44. doi:10.1016/j.jacc.2016.10.066.
  10. Carroll JD, Mack MJ, Vemulapalli S, Herrmann HC, et al. STS-ACC TVT Registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:2492–516. doi:10.1016/j.jacc.2020.09.595.
  11. Carroll JD, Vemulapalli S, Dai D, Matsouaka R, et al. Procedural experience for transcatheter aortic valve replacement and relation to outcomes. J Am Coll Cardiol. 2017;70:29. doi:10.1016/j.jacc.2017.04.056.
  12. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–92. doi:10.1016/S0140-6736(17)30757-2.
  13. Chamandi C, Puri R, Rodriguez-Gabella T, Rodés-Cabau J. Latest-generation transcatheter aortic valve replacement devices and procedures. Can J Cardiol. 2017;33:1082–90.  doi:10.1016/j.cjca.2017.03.012.
  14. Chambers JB, Garbi M, Nieman K, et al. Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a European Association of Cardiovascular Imaging report of literature review and current practice. Eur Heart J Cardiovasc Imaging. 2017;18:489–98. doi:10.1093/ehjci/jew309.
  15. Christos Eftychiou, Nicolaos Eteocleous, Ioannis Zittis, et al. Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality. Hellenic J Cardiol. 2021;62(1):57–64. doi:10.1016/j.hjc.2020.09.011.
  16. David TE, Armstrong S, Maganti M. Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? Ann Thorac Surg. 2010;90:775–81. doi:10.1016/j.athoracsur.2010.05.034.
  17. de Brito FS, Carvalho LA, Sarmento-Leite R, et al. Brazilian TAVI Registry investigators. Outcomes and predictors of mortality after transcatheter aortic valve implantation: results of the Brazilian registry. Catheter Cardiovasc Interv. 2015;85:E153–E162. doi:10.1002/ccd.25778.
  18. Deharo P, Bisson A, Herbert J, et al. Transcatheter valve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J Am Coll Cardiol. 2020;76(5):489–99. https://doi.org/10.1016/j.jacc.2020.06.010.
  19. Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons / American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016;9:2189–99. doi.org/10.1016/j.jcin.2016.07.026.
  20. Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: the REPRISE III randomized clinical trial. JAMA. 2018;319:27–37. doi:10.1001/jama.2017.19132.
  21. Fröhlich GM, Baxter PD, Malkin CJ, et al. Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (data from the UK TAVI Registry). Am J Cardiol. 2015;116:1555–9. doi:10.1016/j.amjcard.2015.08.035.
  22. Fuchs A, De Backer O, Brooks M, et al. Subclinical leaflet thickening and stent frame geometry in self-expanding transcatheter heart valves. EuroIntervention. 2017;13:e1067–e1075. DOI:10.4244/EIJ-D-17-00373.
  23. Gozdek M, Raffa GM, Suwalski P, et al. SIRIO-TAVI group. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2018;53:495–504. doi:10.1093/ejcts/ezx347.
  24. Greenbaum AB, Neill WW, Paone G, et al. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients. J Am Coll Cardiol. 2014;63:2795. doi:10.1016/j.jacc.
  25. Hamm CW, Arsalan M, Mack MJ. The future of transcatheter aortic valve implantation. Eur Heart J. 2016;37:803–10. doi:10.1093/eurheartj/ehv574.
  26. Husser O, Kim W-K, Pellegrini C, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017;10:2078. doi:10.1016/j.jcin.2017.06.026.
  27. Kapadia SR, Krishnaswamy A. Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement: Connecting Intuition and Proof. J Am Coll Cardiol Intv. 2021;14(2);169–71. DOI:10.1016/j.jcin.2020.11.025.
  28. Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75:1882–93. doi:10.1016/j.jacc.2020.02.051.
  29. Latib A, Naim C, De Bonis M, et al. TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol. 2014;64:2176–8. doi: 10.1016/j.jacc.2014.09.021.
  30. Ledwoch J, Franke J, Gerckens U, et al. German Transcatheter Aortic Valve Interventions Registry Investigators. Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: analysis from the German transcatheter aortic valve interventions registry. Catheter Cardiovasc Interv. 2013;82:E569–E577. doi:10.1002/ccd.24915.
  31. Leon MB, Mack MJ, Hahn RT, et al, PARTNER 3 Investigators. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77:1149–61. doi.org/10.1016/j.jacc.2020.12.052.
  32. Leon MB, Smith CR, Mack M, et al., PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607. doi:10.1056/NEJMoa1008232.
  33. Leon MB, Smith CR, Mack MJ, et al., PARTNER 2 Investiga­tors. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20. doi: 10.1056/NEJMoa1514616.
  34. Liao Y-B, Zhao Z-G, Wei X, et al. Transcatheter aortic valve implantation with the self-expandable venus A-Valve and CoreValve devices: preliminary experiences in China. Catheter Cardiovasc Interv. 2017;89:528–33. doi:10.1002/ccd.26912.
  35. Ludman P. Personal communication: analysis of in-hospital mortality in UK TAVI dataset. 2018. DOI:10.1136/heartjnl-2018-313510.
  36. Ludman P. UK TAVI audit slide set 2007–2016. https://www.bcis.org.uk/education/bcis-audit-report-tavi-2016 (20 April 2018).
  37. Iung B, Cachier A, Baron G, Messika-Zeitoun D, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714–20. doi: 10.1093/eurheartj/ehi471.
  38. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019; 380:1695–705. doi: 10.1056/NEJMoa1814052.
  39. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24. DOI: 10.1056/NEJMoa1509233.
  40. Makkar RR, Thourani VH, Mack MJ, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799–809. DOI:10.1056/NEJMoa1910555.
  41. Mylotte D, Lefevre T, Søndergaard L, Piazza N, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol. 2014;64:2330. doi:10.1016/j.jacc.2014.09.039.
  42. Nazif TM, Dizon José M, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60–9. doi:10.1016/j.jcin.2014.07.022.
  43. Oguri A, Yamamoto M, Mouillet G, et al. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia. Circ Cardiovasc Interv. 2014;7:602. doi:10.1161/CIRCINTERVENTIONS.113.000403.
  44. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin III JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt III TM, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;143:e35–e71. doi.org/10.1161/CIR.0000000000000932.
  45. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–15. DOI: 10.1056/NEJMoa1816885.
  46. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–15. doi:10.1056/NEJMoa1816885.
  47. Reardon MJ, Van Mieghem NM, Popma JJ, SURTAVI Investigators, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31. doi:10.1056/NEJMoa1700456.
  48. Regueiro A, Linke A, Latib A, Ihlemann N, et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA. 2016;316:1083–92. doi:10.1001/jama.2016.12347.
  49. Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65. doi:10.1016/j.jcin.2017.04.014.
  50. Sharma SK, MD, FACC, FSCAI; Rao RS, et al. First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study. Eurointervention. 2020;16(5):421–9. doi:10.4244/EIJ-D-19-00413.
  51. Shen Y, Zhang H MM, Zhang L MD, et al. Transcatheter aortic valve replacement with balloon-expandable valve. Herz. 2018;43(8):746–51. doi: 10.1007/s00059-017-4622-x.
  52. Shimura T, Yamamoto M, Kano S, et al. Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation. 2017;135:2013. doi:10.1161/CIRCULATIONAHA.116.025630.
  53. Siontis GC, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129–40. doi: 10.1016/j.jacc.2014.04.033.
  54. Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–53. doi:10.1093/eurheartj/ehz275.
  55. Siontis GC, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J. 2016;37:3503–12. doi:10.1093/eurheartj/ehw225.
  56. Tam DY, Vo TX, Wijeysundera HC. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;92:1404–11. doi:10.1002/ccd.27686.
  57. Thourani VH, Kodali S, Makkar RR, Herrmann HC, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–25. DOI:https://doi.org/10.1016/S0140-6736(16)30073-3.
  58. Thyregod HG, Steinbruchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184–94. doi:10.1016/j.jacc.2015.03.014.
  59. Thyregod HGH, Ihlemann N, Jorgensen TH, et al. Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation. 2019;139:2714–23. doi:10.1161/CIRCULATIONAHA.118.036606.
  60. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43(7):561–32.  https://doi.org/10.1093/eurheartj/ehab395. 
  61. Walther T, Hamm CW, Schuler G, Berkowitsch A, et al. Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry. J Am Coll Cardiol. 2015;65:2173–80. doi:10.1016/j.jacc.2015.03.034.
  62. Yoon S-H, Bleiziffer S, De Backer O, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2017;69:2579–89.
  63. Yoon S-H, Lefèvre T, Ahn J-M, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2016;68:1195–205. doi:10.1016/j.jacc.2016.06.041.
[PDF] [Contents]  

 

 

Thoracic endovascular aneurysm repair in patients with connective tissue disorders

A.Yu. Shkandala, B.M. Todurov, S.M. Furkalo, A.V. Khokhlov, O.V. Zelenchuk

References

  1. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al. Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006;82(4):1400–5. doi:10.1016/j.athoracsur.2006.04.098.
  2. Arslan-Kirchner M, von Kodolitsch Y, Schmidtke J. The importance of genetic testing in the clinical management of patients with Marfan syndrome and related disorders. Dtsch Arztebl Int. 2008;105(27):483-91. doi:10.3238/arztebl.2008.0483.
  3. Black JH III. Aneurysms caused by connective tissue abnormalities. In: Cronenwett JL, Johnson KW, editors. Rutherford's vascular surgers. 7. Philadelphia: Saunders Elsevier; 2010. pp. 2168-85.
  4. Böckler D, Meisenbacher K, Peters AS, Grond-Ginsbach C, Bischoff MS. Endovascular treatment of genetically linked aortic diseases. Gefasschirurgie. 2017;22(Suppl 1):1–7. doi:10.1007/s00772-016-0221-z.
  5. Botta L, Russo V, La Palombara C, Rosati M, Di Bartolomeo R, Fattori R. Stent graft repair of descending aortic dissection in patients with Marfan syndrome: an effective alternative to open reoperation? J Thorac Cardiovasc Surg. 2009;138(5):1108-14. doi:10.1016/j.jtcvs.2009.03.014.
  6. Cannavale A, Santoni M, Fanelli F, O'Sullivan G. Aortic dissection: novel surgical hybrid procedures. Interv Cardiol. 2017;12(1):56–60. doi:10.15420/icr.2016:16:3.
  7. Cho IJ, Jang SY, Chang HJ, Shin S, Shim CY, Hong GR, et al. Aortic aneurysm screening in a high-risk population: a non-contrast computed tomography study in korean males with hypertension. Korean Circ J. 2014;44(3):162–9. doi:10.4070/kcj.2014.44.3.162.
  8. Cikach F, Desai MY, Roselli EE, Kalahasti V. Thoracic aortic aneurysm: how to counsel, when to refer. Cleve Clin J Med. 2018;85(6):481-92. doi:10.3949/ccjm.85a.17039.
  9. Cikrit DF, Miles JH, Silver D. Spontaneous arterial perforation: the Ehlers-Danlos specter. J Vasc Surg. 1987;5(2):248–55. doi:10.1016/0741-5214(87)90133-9.
  10. Clough RE, Martin-Gonzalez T, Van Calster K, Hertault A, Spear R, Azzaoui R, et al. Endovascular repair of thoracoabdominal and arch aneurysms in patients with connective tissue disease using branched and fenestrated devices. Ann Vasc Surg. 2017;44:158–63. doi:10.1016/j.avsg.2017.05.013.
  11. Cooper M, Black J. Aortic surgery for patients with connective tissue disorders. Indian J Vasc Endovasc Surg. 2015;(2):60–5. doi:10.4103/0972-0820.161943.
  12. Coselli JS, Green SY, Price MD, Hash JA, Ouyang Y, Volguina IV, et al. Results of open surgical repair in patients with Marfan syndrome and distal aortic dissection. Ann Thorac Surg. 2016;101(6):2193–201. doi:10.1016/j.athoracsur.2015.11.008.
  13. Cury M, Zeidan F, Lobato AC. Aortic disease in the young: genetic aneurysm syndromes, connective tissue disorders, and familial aortic aneurysms and dissections. Int J Vasc Med. 2013;2013:267215. doi:10.1155/2013/267215.
  14. Dake MD, Kato N, Mitchell RS, Semba CP, Razavi MK, Shimono T, et al. Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med. 1999;340:1546–52.
  15. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med. 1994;331:1729–34.
  16. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17–27; discussion 27-8. doi:10.1016/s0003-4975(01)03236-2.
  17. den Hartog AW, Franken R, Zwinderman AH, Timmermans J, Scholte AJ, van den Berg MP, et al. The risk for type B aortic dissection in Marfan syndrome. J Am Coll Cardiol. 2015;63(3):246–54. doi:10.1016/j.jacc.2014.10.050.
  18. Di Bartolomeo R, Leone A, Di Marco L, Pacini D. When and how to replace the aortic arch for type A dissection. Ann Cardiothorac Surg. 2016;5(4):383-8. doi:10.21037/acs.2016.07.07.
  19. Di Bartolomeo R, Murana G, Di Marco L, Pantaleo A, Alfonsi J, Leone A, et al. Frozen versus conventional elephant trunk technique: application in clinical practice. Eur J Cardiothorac Surg. 2017;51(suppl 1):i20-8. doi:10.1093/ejcts/ezw335.
  20. Di Cesare E, Splendiani A, Barile A, Squillaci E, Di Cesare A, Brunese L, et al. CT and MR imaging of the thoracic aorta. Open Med (Wars). 2016;11(1):143–51. doi:10.1515/med-2016-0028.
  21. Di Eusanio M, Trimarchi S, Peterson MD, Myrmel T, Hughes GC, Korach A, et al. Root replacement surgery versus more conservative management during type A acute aortic dissection repair. Ann Thorac Surg. 2014;98(6):2078-84. doi:10.1016/j.athoracsur.2014.06.070.
  22. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–9. doi:10.1038/352337a0.
  23. Dong Z, Fu W, Wang Y, Wang C, Yan Z, Guo D, et al. Stent graft-induced new entry after endovascular repair for Stanford type B aortic dissection. J Vasc Surg. 2010;52(6):1450–7. doi:10.1016/j.jvs.2010.05.121.
  24. Eid-Lidt G, Gaspar J, Meléndez-Ramírez G, Cervantes SJ, González-Pacheco H, Dámas de Los Santos F, et al. Endovascular treatment of type B dissection in patients with Marfan syndrome: mid-term outcomes and aortic remodeling. Catheter Cardiovasc Interv. 2013;82(7):E898–905. doi:10.1002/ccd.24725.
  25. Esposito G, Cappabianca G, Bichi S, Cricco A, Albano G, Anzuini A. Hybrid repair of type A acute aortic dissections with the Lupiae technique: ten-year results. J Thorac Cardiovasc Surg. 2015;149(2 Suppl):S99–104. doi:10.1016/j.jtcvs.2014.07.099.
  26. Geisbüsch P, Kotelis D, von Tengg-Kobligk H, Hyhlik-Dürr A, Allenberg JR, Böckler D. Thoracic aortic endografting in patients with connective tissue diseases. J Endovasc Ther. 2008;15(2):144–9. doi:10.1583/07-2286.1.
  27. Ghanta RK, Green SY, Price MD, Arredondo CC, Wainwright D, Preventza O, et al. Midterm survival and quality of life after extent II thoracoabdominal aortic repair in Marfan syndrome. Ann Thorac Surg. 2016;101(4):1402–9; discussion 1409. doi:10.1016/j.athoracsur.2015.10.018.
  28. Grabenwöger M, Alfonso F, Bachet J, Bonser R, Czerny M, Eggebrecht H, et al. Thoracic endovascular aortic repair (TEVAR) for the treatment of aortic diseases: a position statement from the European association for cardio-thoracic surgery (EACTS) and the European society of cardiology (ESC), in collaboration with the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2012;33(13):1558–63. doi:10.1093/eurheartj/ehs074.
  29. Harky A, Chan J, MacCarthy-Ofosu B. The future of stenting in patients with type A aortic dissection: a systematic review. J Int Med Res. 2020;48(1):300060519871372. doi:10.1177/0300060519871372.
  30. Harky A, Chan JSK, Wong CHM, Francis N, Grafton-Clarke C, Bashir M. Systematic review and meta-analysis of acute type B thoracic aortic dissection, open, or endovascular repair. J Vasc Surg. 2019;69(5):1599–1609.e2. doi:10.1016/j.jvs.2018.08.187.
  31. Harky A, Garner M, Roberts N. A late presentation of Loeys-Dietz syndrome associated with an aortic root aneurysm. Ann R Coll Surg Engl. 2017;99(3):e114–5. doi:10.1308/rcsann.2017.0018.
  32. Harky A, Iqbal R, Giordano V, Al-Adhami A. Aortic endovascular stenting in patients with systemic connective tissue disorders: does the prohibitive dogma still stand tall? [(published online ahead of print, 2019 Jul 29)]. J Int Med Res. 2019;300060519863963. doi:10.1177/0300060519863963.
  33. Harky A, Kai Chan JS, Ming Wong CH, Bashir M. Open versus Endovascular Repair of Descending Thoracic Aortic Aneurysm Disease: A Systematic Review and Meta-analysis. Ann Vasc Surg. 2019;54:304–315.e5. doi:10.1016/j.avsg.2018.05.043.
  34. Harky A, Fan K, Fan K. The genetics and biomechanics of thoracic aortic diseases. Vascular Biology. 2019;1(1):R13-R25. https://doi.org/10.1530/VB-19-0027.
  35. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, American association for thoracic surgery, American college of radiology, American stroke association, society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, society of interventional radiology, society of thoracic surgeons, and society for vascular medicine. Circulation. 2010;121(13):e266–369. Erratum in: Circulation. 2010;122(4):e410. doi:10.1161/CIR.0b013e3181d4739e.
  36. Ince H, Rehders TC, Petzsch M, Kische S, Nienaber CA. Stent-grafts in patients with marfan syndrome. J Endovasc Ther. 2005;12(1):82–8. doi:10.1583/04-1415MR.1.
  37. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005;111(6):816–28. doi:10.1161/01.CIR.0000154569.08857.7A.
  38. Kalkat MS, Rahman I, Kotidis K, Davies B, Bonser RS. Presentation and outcome of Marfan's syndrome patients with dissection and thoraco-abdominal aortic aneurysm. Eur J Cardiothorac Surg. 2007;32(2):250-4. doi:10.1016/j.ejcts.2007.04.013.
  39. Kalra A, Harris KM, Kische S, Alden P, Schumacher C, Nienaber CA. Endovascular repair of descending thoracic aorta in Loeys-Dietz II syndrome. Ann Vasc Surg. 2015;29(7):1452.e17-21. doi: 10.1016/j.avsg.2015.04.071.
  40. Kazui T, Inoue N, Yamada O, Komatsu S. Selective cerebral perfusion during operation for aneurysms of the aortic arch: a reassessment. Ann Thorac Surg. 1992;53(1):109–14. doi:10.1016/0003-4975(92)90767-x.
  41. Keschenau PR, Kotelis D, Bisschop J, Barbati ME, Grommes J, Mees B, et al. Editor's choice-open thoracic and thoraco-abdominal aortic repair in patients with connective tissue disease. Eur J Vasc Endovasc Surg. 2017;54(5):588–96. doi:10.1016/j.ejvs.2017.07.026.
  42. LeMaire SA, Carter SA, Volguina IV, Laux AT, Milewicz DM, Borsato GW, et al. Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. Ann Thorac Surg. 2006;81(6):2063-78; discussion 2078. doi:10.1016/j.athoracsur.2006.01.070.
  43. Leshnower BG, Chen EP. When and how to replace the aortic root in type A aortic dissection. Ann Cardiothorac Surg. 2016;5(4):377-82. doi:10.21037/acs.2016.03.15.
  44. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–81. doi:10.1038/ng1511.
  45. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355(8):788–98. doi:10.1056/NEJMoa055695.
  46. Majumder PP, St Jean PL, Ferrell RE, Webster MW, Steed DL. On the inheritance of abdominal aortic aneurysm. Am J Hum Genet. 1991;48(1):164–70.
  47. Marcheix B, Rousseau H, Bongard V, Heijmen RH, Nienaber CA, Ehrlich M, et al. Stent grafting of dissected descending aorta in patients with Marfan's syndrome: mid-term results. JACC Cardiovasc Interv. 2008;1(6):673-80. doi:10.1016/j.jcin.2008.10.005.
  48. Marfan ABJ. Un cas de déformation congénitale des quatre membres, plus prononcée aux extrémités, caractérisée par l'allongement des os avec un certain degré d'amincissement. Paris: Impr. Maretheux, 1896.
  49. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005;111(11):e150-7. doi:10.1161/01.CIR.0000155243.70456.F4.
  50. Mommertz F, Sigala S, Langer TA, Koeppel WH, Mess GW, Schurink MJ, et al. Thoracoabdominal aortic aneurysm repair in patients with marfan syndrome. Eur J Vasc Endovasc Surg. 2008;35(2):181-6. doi:10.1016/j.ejvs.2007.10.013.
  51. Nienaber CA, Fattori R, Lund G, Dieckmann C, Wolf W, von Kodolitsch Y, et al. Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. N Engl J Med. 1999;340:1539–45.
  52. Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt grafts in aortic dissection (INSTEAD) trial. Circulation. 2009;120(25):2519–28. doi:10.1161/CIRCULATIONAHA.109.886408.
  53. Nordon IM, Hinchliffe RJ, Holt PJ, Morgan R, Jahangiri M, Loftus IM, et al. Endovascular management of chronic aortic dissection in patients with Marfan syndrome. J Vasc Surg. 2009;50(5):987-91. doi:10.1016/j.jvs.2009.05.056.
  54. Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg. 2005;42(1):98–106. doi:10.1016/j.jvs.2005.03.053.
  55. Omura A, Tanaka A, Miyahara S, Sakamoto T, Nomura Y, Inoue T, et al. Early and late results of graft replacement for dissecting aneurysm of thoracoabdominal aorta in patients with Marfan syndrome. Ann Thorac Surg. 2012;94(3):759–65. doi:10.1016/j.athoracsur.2012.04.061.
  56. Ouriel K, Greenberg RK, Clair DG, O'hara PJ, Srivastava SD, Lyden SP, et al. Endovascular aneurysm repair: gender-specific results. J Vasc Surg. 2003;38(1):93–8. doi:10.1016/s0741-5214(03)00127-7.
  57. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673–80. Erratum in: N Engl J Med. 2001;344(5):392. doi:10.1056/NEJM200003093421001.
  58. Pilop C, Aregger F, Gorman RC, Brunisholz R, Gerrits B, Schaffner T, et al. Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation. 2009;120(11):983–91. Erratum in: Circulation. 2010;121(6):e38. doi:10.1161/CIRCULATIONAHA.108.843516.
  59. Rozado J, Martin M, Pascual I, Hernandez-Vaquero D, Moris C. Comparing American, European and Asian practice guidelines for aortic diseases. J Thorac Dis. 2017;9(Suppl 6):S551–60. doi:10.21037/jtd.2017.03.97.
  60. Sandford RM, Bown MJ, London NJ, Sayers RD. The gene­tic basis of abdominal aortic aneurysms: a review. Eur J Vasc Endovasc Surg. 2007;33(4):381-90. doi:10.1016/j.ejvs.2006.10.025.
  61. Sun JCJ. Genetic disorders of the thoracic aorta and indications for surgery. Cardiol Clin. 2017;35(3):317–20. doi:10.1016/j.ccl.2017.03.003.
  62. Superti-Furga A, Steinmann B, Byers PH. Type III collagen deficiency. Lancet. 1989;1(8643):903-4. doi:10.1016/s0140-6736(89)92899-7.
  63. Svensson LG, Kouchoukos NT, Miller DC, Bavaria JE, Coselli JS, Curi MA, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg. 2008;85(1):S1–41. doi:10.1016/j.athoracsur.2007.10.099.
  64. Tjaden B, Azizzadeh A. Endovascular therapy in Marfan syndrome: PRO. Ann Cardiothorac Surg. 2017;6(6):672–6. doi:10.21037/acs.2017.10.06.
  65. Volodos NL, Shekhanin VE, Karpovich IP, Troian VI, Gur’ev I. A self-fixing synthetic blood vessel endoprosthesis. Vestn Khir Im I I Grek. 1986;137:123–5.
  66. von Kodolitsch Y, De Backer J, Schüler H, Bannas P, Behzadi C, Bernhardt AM, et al. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. Appl Clin Genet. 2015;8:137–55. doi:10.2147/TACG.S60472.
  67. Waterman AL, Feezor RJ, Lee WA, Hess PJ, Beaver TM, Martin TD, et al. Endovascular treatment of acute and chronic aortic pathology in patients with Marfan syndrome. J Vasc Surg. 2012;55(5):1234-40; discussion 1240-1. doi:10.1016/j.jvs.2011.11.089.
  68. Webster MW, St Jean PL, Steed DL, Ferrell RE, Majumder PP. Abdominal aortic aneurysm: results of a family study. J Vasc Surg. 1991;13(3):366–72. doi:10.1067/mva.1991.26359.
  69. Williams JA, Loeys BL, Nwakanma LU, Dietz HC, Spevak PJ, Patel ND, et al. Early surgical experience with Loeys-Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. Ann Thorac Surg. 2007;83(2):S757-63; discussion S785-90. doi:10.1016/j.athoracsur.2006.10.091.
  70. Yokoi Y, Azuma T, Yamazaki K. Advantage of a precurved fenestrated endograft for aortic arch disease: simplified arch aneurysm treatment in Japan 2010 and 2011. J Thorac Cardiovasc Surg. 2013;145(3):S103–9. doi:10.1016/j.jtcvs.2012.11.058.
  71. Yuan SM, Jing H. Cystic medial necrosis: pathological findings and clinical implications. Rev Bras Cir Cardiovasc. 2011;26(1):107-15. Erratum in: Rev Bras Cir Cardiovasc. 2012;27(1):173. doi:10.1590/s0102-76382011000100019.
  72. Zhang H, Qiao T. Aortic remodeling in type B aortic dissection after thoracic endovascular aortic repair with an aortic extender cuff implantation. Clin Interv Aging. 2018;13:2359–66. doi:10.2147/CIA.S179526.
[PDF] [Contents]  

 

 

Sudden cardiac risk assessment in hypertrophic cardiomyopathy: role of the imaging

N.D. Oryshchyn

References

  1. Руденко К.В., Лазоришинец В.В., Трембовецкая Е.М., Невмержицкая Л.А. The results of surgical treatment of patients with hypertrophic obstructive cardiomyopathy as a risk factor of sudden cardiac death. Свiт медицини та бiологiї. 2020. №16 (2). С. 104–114. doi:10.26724/2079-8334-2020-2-72-109-114.
  2. Bhopalwala H, Dewaswala N, Liu S, et al. Conversion of left atrial volume to diameter for automated estimation of sudden cardiac death risk in hypertrophic cardiomyopathy. Echocardiography. 2021;38:183–8.
  3. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J – Cardiovasc Imaging. 2015;16(3):280.
  4. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrastenhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130:484–495.
  5. Chan RH, Maron BJ, Olivotto I, et al. Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:436–41.
  6. Choi EY, Rim SJ, Ha JW, et al. Phenotypic spectrum and clinical characteristics of apical hypertrophic cardiomyopathy: multicenter echo-Doppler study. Cardiology. 2008;110(1):53–61.
  7. Elliott PM, Gimeno JR, Tome´ MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–41.
  8. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.
  9. Finocchiaro G, PapadakisM, Tanzarella G, et al. Sudden death can be the first manifestation of hypertrophic cardiomyopathy: data from a United Kingdom Pathology Registry. JACC Clin Electrophysiol. 2019;5:252–4.
  10. Freitas P, Ferreira AM, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson. 2019;15;21(1):50. doi:10.1186/s12968-019-0561-4
  11. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–96.
  12. Greulich S, Seitz A, Herter D, Günther F, Probst S, Bekeredjian R, Gawaz M, Sechtem U, Mahrholdt H. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study. Eur Heart J – Cardiovasc Imaging. 2021;22(7):732–41. https://doi.org/10.1093/ehjci/jeaa423.
  13. Klopotowski M, Kukula K, Lukasz A, et al. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68:49–56.
  14. Li X, Lai L, Luo R, et al. The clinical prognosis of presence and location of late gadolinium enhancement by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a single-center cohort study. J Cardiovasc Transl Res. 2021;14(5):1001–16. DOI:10.1007/s12265-021-10107-x.
  15. Maron MS, Olivotto I, Betocchi S. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
  16. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation. 2006;114(15):1633–44.
  17. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12.
  18. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541–9.
  19. Maron BJ, Casey SA, Chan RH, et al. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:757–64.
  20. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583– 8.
  21. Mentias A, Raeisi-Giglou P, Smedira NG. Late Gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am College of Cardiology. 2018;72(8):857–70.
  22. Mills H, Espersen K, Jurlander R, et al. Prevention of sudden cardiac death in hypertrophic cardiomyopathy: risk assessment using left atrial diameter predicted from left atrial volume. Clin Cardiol. 2020;43:581–6.
  23. Minami Y, Haruki S, Yashiro B, et al. Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. Cardiol. 2016;68:478–84.
  24. Minami Y, Haruki S, Hagiwara N. Phenotypic overlap in hypertrophic cardiomyopathy: apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol. 2014;64(6):463–9. doi:10.1016/j.jjcc.2014.03.003. Epub 2014 Apr 24. PMID: 24768408.
  25. Nguyen A, Schaff HV. Electrical storms in patients with apical aneurysms and hypertrophic cardiomyopathy with midventricular obstruction: A case series. J Thorac Cardiovasc Surg. 2017;154(6):e101–e103.
  26. O’Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137:1015–23.
  27. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: executive summary: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e533–e557.
  28. Pozios I, Corona-Villalobos C, Sorensen LL. Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(6):938–44. doi:10.1016/j.amjcard.2015.06.018. Epub 2015 Jun 26. PMID: 26239580; PMCID: PMC4554842.
  29. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017; 69:761–773.
  30. Rowin EJ, Sridharan A, Madias C. Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy. Am J Cardiol. 2020;128:75–83. 
  31. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;(65):1249–54.
  32. Śpiewak M, Kłopotowski M, Kowalik E, et al. Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging. Sci Rep. 2021;11(1):7146. doi: 10.1038/s41598-021-86532-4. PMID: 33785804; PMCID: PMC8009882.
  33. Spirito P, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85.
  34. Yang H, et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr. 2005;18(10):1074–82.
  35. Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016; 9:1392–1402.
[PDF] [Contents]  

 

 

Performance index – a new approach to the assessment of left ventricular systolic function

V.I. Pavliuk, О.A. Myshakivsky, M.V. Voytsekhivska, O.J. Zharinov

References

  1. Павлюк В.І., Жарінов О.Й., Чубучний В.М. та ін. Новий метод ехокардіографічної оцінки фракції викиду та обґрунтування застосування каптоприлу у хворих з гострим інфарктом міокарда. Укр. кардіол. журн. 1997. №  4. С. 8–10.
  2. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. Москва: МедиаСфера, 2002. 312 с. https://www.twirpx.com/file/1440496/
  3. Armstrong WF, Ryan T. Feigenbaum`s Echocardiography. Wolters Kluwer, 2019. 771 p.
  4. Aurigemma GP. Quantitative evaluation of left ventricular structure, wall stress and systolic function. In Otto CM (ed): The Practice of Clinical Echocardiography. 5th ed. Philadelphia: Elsevier, 2017. pp 107–127.
  5. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. A report of the heart failure society of America, hart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Cardiac Fail. 2021;27(4):387–413. DOI:10.1002/ejhf.2115
  6. Chandra S, Skali H, Blankstein R. Novel techniques for assessment of left ventricular systolic function. Heart Fail Rev. 2011;16(4):327–37. DOI: 10.1007/s10741-010-9219-x.
  7. Claus P, Omar AMS, Pedrizzeti G, Sengupta PP, Nagel E. Tissue tracking technology for assessing cardiac mechanics: principles, normal values, and clinical applications. JACC Cardiovasc Imaging. 2015;8(12):1444–60. DOI:10.1016/j.jcmg.2015.11.001.
  8. Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol. 2017;69(8):1043–56. DOI:10.1016/j.jacc.2016.12.012.
  9. Dumesnil J, Dion D, Yvorchuk K, et al. A new, simple and accurate method for determining ejection fraction by Doppler echocardiography. Can J Cardiol. 1995;11(11): 1007–14. https://pubmed.ncbi.nlm.nih.gov/8542542/.
  10. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39. DOI:10.1016/j.echo.2014.10.003.
  11. Marwick TH. Methods used for the assessment of LV systolic function: common currency or tower of Babel? Heart. 2013;99(15):1078–86. DOI:10.1136/heartjnl-2012-303433.
  12. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab670.
  13. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24(3):77–313. DOI:10.1093/ejechocard/jer021.
  14. Nicolosi GL. The strain and strain rate imaging paradox in echocardiography: overabundant literature in the last two decades but still uncertain clinical utility in an individual case. Arch Med Sci Atheroscler Dis. 2020;26(5):e297–e305. doi:10.5114/amsad.2020.103032.
  15. Otto CM. Textbook of clinical echocardiography. Elsevier, 2018. 575 p.
  16. Palmieri V, Manganelli F, Russo C, et al. Accuracy and feasiability of simplified Doppler-based left ventricular ejection fraction. Am J Cardiol. 2013;112(6):889–94. DOI:10.1016/j.amjcard.2013.05.019.
  17. Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):260–74. https://doi.org/10.1016/j.jcmg.2017.11.017
  18. Riffenburgh R. Statistics in Medicine. 3rd ed. Academic Press, 2012. 744 p.
  19. Tan C, Rubenson D, Srivastava A, et al. Left ventricular outflow tract velocity time integral outperforms ejection fraction and Doppler-derived cardiac output for predicting outcomes in a select advanced heart failure cohort. Cardiovasc Ultrasound. 2017;15(1):18. doi:10.1186/s12947-017-0109-4.
  20. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013;26(2):185–91. doi:10.1016/j.echo.2012.10.008.
[PDF] [Contents]  

 

 

Predictors of sinus rhythm restoration in patients with long-term episodes of persistent atrial fibrillation

Ya.V. Skybchyk, К.О. Mikhaliev, O.J. Zharinov

References

  1. Фібриляція і тріпотіння передсердь / За ред. О.Й. Жа­­­рінова, В.О. Куця. Київ: Четверта хвиля, 2022. 248 с.
  2. Akamatsu K, Ito T, Ozeki M, Miyamura M, Sohmiya K, Hoshiga M. Left atrial spontaneous echo contrast occurring in patients with low CHADS2 or CHA2DS2-VASc scores. Cardiovasc Ultrasound. 2020;18(1):31. doi:10.1186/s12947-020-00213-2.
  3. Benussi S, de Maat GE. Atrial remodelling and function: implications for atrial fibrillation surgery. Eur J Cardiothorac Surg. 2018;53(suppl_1):i2–i8. doi:10.1093/ejcts/ezx340.
  4. Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol. 1985;6(4):744–9. doi:10.1016/s0735-1097(85)80476-9.
  5. Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991;18(2):398–404. doi:10.1016/0735-1097(91)90592-w.
  6. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen  PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis  AB, Davies DW, Day JD, d’Avila A, Natasja de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai  K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca  M, Schilling R, Tondo C, Tsao  HM, Verma A, Wilber DJ, Yamane T; Document Reviewers. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–e160. doi:10.1093/europace/eux274.
  7. Daniel WG, Nellessen U, Schröder E, Nonnast-Daniel B, Bednarski P, Nikutta P, Lichtlen PR. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol. 1988;11(6):1204–11. doi:10.1016/0735-1097(88)90283-5. 
  8. de Vos CB, Crijns HJ, Tieleman RG. The fibrillating atrial myocardium visualized: an unexploited source of information. Heart Rhythm. 2009;6(8):1247–8. doi:10.1016/j.hrthm.2008.11.003. 
  9. Donghua Z, Jian P, Zhongbo X, Feifei Z, Xinhui P, Hao Y, Fuqiang L, Yan L, Yong X, Xinfu H, Surong M, Muli W, Dingli X. Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol. 2013;36(1):27–32; discussion 32. doi:10.1007/s10840-012-9727-9.
  10. Dudink EAMP, Erküner Ö, Berg J, Nieuwlaat R, de Vos CB, Weijs B, Capucci A, Camm AJ, Breithardt G, Le Heuzey JY, Luermans JGLM, Crijns HJGM. The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. Europace. 2018;20(6):929–34. doi:10.1093/europace/eux217.
  11. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart. 2015;101(19):1526–30. doi:10.1136/heartjnl-2015-307656. 
  12. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen  SA, Chugh SS, Corradi D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner  DR, Nattel  S; Document Reviewers: EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455–90. doi:10.1093/europace/euw161.
  13. Grebmer C, Lennerz C, Brkic A, Blazek P, Weigand S, Semmler  V, Kottmaier M, Bourier F, Friedrich L, Risse E, Brooks S, Kornmayer M, Telishevska M, Reents T, Kolb  C, Hessling G, Deisenhofer I. Prevalence and clinical correlates of spontaneous echo contrast in patients on oral anticoagulation undergoing catheter ablation for atrial fibrillation. Int J Clin Cardiol. 2019;6:151. doi.org/10.23937/2378-2951/1410151.
  14. Gumprecht J, Szulik M, Domek M, Mazurek M, Shantsila  A, Oxborough D, Lip GYH. Novel echocardiographic biomarkers in the management of atrial fibrillation. Curr Cardiovasc Imaging Rep. 2019;12:43. doi:10.1007/s12410-019-9520-6.
  15. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blom­­ström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane  DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas  GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612.
  16. Inácio JF, da Rosa Mdos S, Shah J, Rosário J, Vissoci JR, Manica  AL, Rodrigues CG. Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis. Resuscitation. 2016;100:66–75. doi: 10.1016/j.resuscitation.2015.12.009.
  17. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. doi:10.1038/bmt.2012.244.
  18. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan  A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck  KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas  P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–116. doi:10.1056/NEJMoa2019422.
  19. Kirkland S, Stiell I, AlShawabkeh T, Campbell S, Dickinson  G, Rowe BH. The efficacy of pad placement for electrical cardioversion of atrial fibrillation/flutter: a systematic review. Acad Emerg Med. 2014;21(7):717–26. doi:10.1111/acem.12407. 
  20. Konrad T, Theis C, Mollnau H, Sonnenschein S, Ocete  BQ, Bock K, Münzel T, Rostock T. Primary persistent atrial fibrillation: A distinct arrhythmia subentity of an ablation population. J Cardiovasc Electrophysiol. 2015;26(12):1289–94. doi:10.1111/jce.12818.
  21. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36(46):3250–7. doi:10.1093/eurheartj/ehv513.
  22. Kottkamp H, Schreiber D. The Substrate in «Early Persistent» atrial fibrillation: arrhythmia induced, risk factor induced, or from a specific fibrotic atrial cardiomyopathy? JACC Clin Electrophysiol. 2016;2(2):140–2. doi:10.1016/j.jacep.2016.02.010. 
  23. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24(3):755–62. doi:10.1016/0735-1097(94)90025-6. 
  24. Lim HS, Denis A, Middeldorp ME, Lau DH, Mahajan R, Derval N, Albenque JP, Boveda S, Zellerhoff S, Yamashita  S, Berte B, Mahida S, Komatsu Y, Daly M, Jesel L, Pomier C, Meillet V, Dubois R, Amraoui S, Shah A, Sacher F, Cochet  H, Hocini M, Jaïs P, Sanders P, Haïssaguerre M. Persistent Atrial Fibrillation From the Onset: A Specific subgroup of patients with biatrial substrate involvement and poorer clinical outcome. JACC Clin Electrophysiol. 2016;2(2):129–39. doi:10.1016/j.jacep.2015.12.014. 
  25. Limantoro I, de Vos CB, Delhaas T, Weijs B, Blaauw Y, Schotten U, Kietselaer B, Pisters R, Crijns HJ. Clinical correlates of echocardiographic tissue velocity imaging abnormalities of the left atrial wall during atrial fibrillation. Europace. 2014;16(11):1546–53. doi:10.1093/europace/euu047.
  26. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner DJ, Scheiner MA, Lerman BB. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101(11):1282–7. doi:10.1161/01.cir.101.11.1282.
  27. Miyazaki S, Ito T, Suwa M, Nakamura T, Kobashi A, Kitaura Y. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J. 2001;65(10):874–8. doi: 10.1253/jcj.65.874.
  28. Ronsoni RM, Saffi MAL, Gonçalves MVM, Nakayama IH, Luz Leiria TL. A new vision at the interface of atrial fibrillation and stroke. Front Cardiovasc Med. 2021;8:689313. doi:10.3389/fcvm.2021.689313.
  29. Schmidt AS, Lauridsen KG, Torp P, Bach LF, Rickers H, Løfgren  B. Maximum-fixed energy shocks for cardioverting atrial fibrillation. Eur Heart J. 2020;41(5):626–31. doi:10.1093/eurheartj/ehz585.
  30. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeus­ler  KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel  H; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76. doi:10.1093/europace/euab065.
  31. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes (KDIGO) СKD Work Group. KDIGO 2012. Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney International. 2013;3(suppl.):1–150. doi:10.7326/0003-4819-158-11-201306040-00007.
  32. Thomas L, Abhayaratna WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging. 2017;10(1):65–77. doi:10.1016/j.jcmg.2016.11.003. 
  33. Um KJ, McIntyre WF, Healey JS, Mendoza PA, Koziarz  A, Amit G, Chu VA, Whitlock RP, Belley-Côté EP. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21(6):856–63. doi:10.1093/europace/euy310.
  34. Wałek P, Sielski J, Gorczyca I, Roskal-Wałek J, Starzyk K, Jaskulska-Niedziela E, Bartkowiak R, Wożakowska-Kapłon  B. Left atrial mechanical remodelling assessed as the velocity of left atrium appendage wall motion during atrial fibrillation is associated with maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation. PLoS One. 2020;15(1):e0228239. doi:10.1371/journal.pone.0228239.
  35. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Gessler N, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Ng GA, Schnabel RB, Suling  A, Szumowski L, Themistoclakis S, Vardas P, van Gelder IC, Wegscheider K, Kirchhof P. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43(12):1219–30. doi:10.1093/eurheartj/ehab593.
[PDF] [Contents]  

 

 

Clinical case of Fabry disease: an interesting finding in cardiac surgery patient

O.A. Yepanchintseva, А.S. Solonovych, А.V. Besaga, O.J. Zharinov

References

  1. Волгина С.Я. Болезнь Фабри. Практическая медицина (научно-практический медицинский журнал). 2012. № 7 (62). С. 75–79.
  2. Горовенко Н.Г., Ліщишина О.М., Дороніна Я.Г. та ін. Хвороба Фабрі: клінічна настанова, заснована на доказах. 2018. 79 с.
  3. Фирсов К.В., Котов А.С. Неврологические проявления при болезни Фабри. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016. № 116 (9). С. 98–105. https://doi.org/10.17116/jnevro20161169198-105
  4. Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351–8. doi: 10.1136/jmedgenet-2017-104863.
  5. Azevedo O, Gal A, Faria R, Gaspar P, Miltenberger-Miltenyi G, Gago F, Dias F, Martins A, Rodrigues J, Reimao P, Pereira O, Simoen S, Lopez E, Guimaraes MJ, Sousa N, Cunha D. Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype. Mol Genet Metab. 2020;129:150–60.
  6. Barbey F, Qanadli S, Juli C, Brakch N, Palaek T, Rizzo E, Jeanrenaud X, Eckhardt B, Linhart A. Aortic remodelling in Fabry disease. Eur Heart J. 2010;31(3):347–53. https://doi.org/10.1161/CIRCULATIONAHA.114.009789
  7. Barold SS. Arrhythmias: changing indications for biventricular pacing in bradycardia. Nat Rev Cardiol. 2013;10:436–8. doi: 10.1038/nrcardio.2013.88. 
  8. Bénichou B, Goyal S, Sung C, Norfleet AM, O’Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96:4–12. doi: 10.1016/j.ymgme.2008.10.004.
  9. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15:1070–118. doi:10.1093/europace/eut206. Epub 2013 Jun 24.
  10. Brogden G, Shammas H, Maalouf K, Samara LN, Wetzel G, Amiri M, Köckritz-Blickwede M, Das AM, Naim HY. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro. Biosci Rep. 2017;37(2):BSR20160402. doi:10.1042/BSR20160402. PMID: 28351893; PMCID: PMC5408660.
  11. Calcagnino M, O’Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K, Mehta A, Hughes D, Murphy E, Lachmann R. Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson–Fabry disease. J Am Coll Cardiol. 2011;58:88–9.
  12. Chan B, Adam DN. A Review of Fabry Disease. Skin Therapy Lett. 2018;23(2):4–6. PMID: 29562089.
  13. Choi L, Vernon J, Kopach O, Minett MS, Mills K, Clayton PT, Meert T, Wood JN. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett. 2015;594:163–8. doi:10.1016/j.neulet.2015.01.084. 
  14. De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld  PA. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93–9. doi:10.1016/j.ymgme.2013.02.003.
  15. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, mor­­phologic, and biochemical studies. Circulation. 1976;54(5):818–25. doi: 10.1161/01.cir.54.5.818. PMID: 824066.
  16. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel  C, Iwanochko RM, Thavendiranathan P, Crean AM. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson. 2016;18:14. doi: 10.1186/s12968-016-0233-6.
  17. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55(4):261–8. doi:10.1136/jmedgenet-2017-105080.
  18. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Mol Genet Metab. 2021;134(1–2):117–31. doi:10.1016/j.ymgme.2021.07.006.
  19. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopou­­los P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. doi:10.1093/eurheartj/ehu284.
  20. Eng C, Germain D, Banikazemi M, Warnock DG, Wanner C, Hopkin RG, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2008;8:539–48. https://doi.org/10.1097/01.gim.0000237866.70357.c6.
  21. FDA approves new treatment for a rare genetic disorder, Fabry disease. URL: https://www.fda.gov/news-events/press-announcements/ | FDA.
  22. Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131(1–2):219–28. doi:10.1016/j.ymgme.2020.07.007.
  23. Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P, Boot RG, Willems LI, Overkleeft HS, Aerts JM. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta. 2014;1841(5):811–25. doi:10.1016/j.bbalip.2013.11.004.
  24. Ferreira S, Auray-Blais C, Boutin M, Lavoie P, Nunes JP, Martins E, Garman S, Oliveira JP. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clin Chim Acta. 2015;447:96–104. doi:10.1016/j.cca.2015.06.003.
  25. Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257–62. doi:10.1016/j.ijcard.2017.06.079. Epub 2017 Jun 23. PMID: 28688718.
  26. Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, Alfarano M, Russo MA, Chimenti C. Immune-mediated myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc. 2018;7(17):e009052. doi:10.1161/JAHA.118.009052. PMID: 30371172; PMCID: PMC6201436.
  27. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30. PMID: 21092187; PMCID: PMC3009617.
  28. Germain, DP, Fouilhoux A, Decramer S, Tardieu M, Pillet  P, Fila M, Rivera S, Deschênes G, Lacombe D. Consensus re­­commendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin genetics. 2019;96(2):107–17. https://doi.org/10.1111/cge.13546.
  29. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251(5):564–570. doi:10.1007/s00415-004-0364-9. PMID: 15164189.
  30. Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, War-nock DG, Wilcox WR. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016;119(1–2):151–9. doi:10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. PMID: 27510433.
  31. Ikari Y, Kuwako K, Yamaguchi T. Fabry’s disease with complete atrioventricular block: histological evidence of invol­­vement of the conduction system. Br Heart J. 1992;68(3):323–5. doi:10.1136/hrt.68.9.323.
  32. Kaissarian N, Kang J, Shu L, Ferraz MJ, Aerts JM, Shayman JA. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells. Mol Genet Metab. 2018;125(4):338–44. doi:10.1016/j.ymgme.2018.10.007. Epub 2018 Nov 2. PMID: 30413389; PMCID: PMC6554739.
  33. Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry disease: molecular basis, pathophysio­­logy, diagnostics and potential therapeutic directions. Biomolecules. 2021;11(2):271. doi:10.3390/biom11020271. PMID: 33673160; PMCID: PMC7918333.
  34. Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, Moon JC, Figtree GA. Cardiac involve­­­­­­ment in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart. 2016;102(4):298–302. doi:10.1136/heartjnl-2015-308494. Epub 2016 Jan 4. PMID: 26729695.
  35. Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635–45. doi:10.1007/s40265-021-01486-1. Epub 2021 Mar 15. PMID: 33721270; PMCID: PMC8102455.
  36. Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Multicenter Female Fabry Study (MFFS) – clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88. doi:10.1186/s13023-016-0473-4. PMID: 27356758; PMCID: PMC4928260.
  37. Lidove O, Zeller V, Chicheportiche V, Meyssonnier V, Sené T, Godot S, Ziza JM. Musculoskeletal manifestations of Fabry disease: A retrospective study. Joint Bone Spine. 2016;83(4):421–6. doi:10.1016/j.jbspin.2015.11.001. Epub 2015 Dec 14. PMID: 26697993.
  38. Linhart A. The heart in Fabry disease. Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis, 2006. Chapter 20. PMID: 21290675.
  39. Linhart A, Germain DP, Olivotto, Akhtar MM, Anastasa­­kis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076–96.
  40. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, Zeman J, Ledvinová J, Poupetová H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8. doi:10.1067/mhj.2000.105105. PMID: 10827394.
  41. Loso J, Lund N, Avanesov M, Muschol N, Lezius S, Cordts K, Schwedhelm E, Patten M. Serum biomarkers of endothelial dysfunction in Fabry associated cardiomyopathy. Frontiers in cardiovasc med. 2018;5:108. https://doi.org/10.3389/fcvm.2018.00108
  42. Lücke T, Höppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004;82(1):93–7. doi:10.1016/j.ymgme.2004.01.011. PMID: 15110329.
  43. Marek J, Palecek T, Magne J, Lavergne D, Boulogne C, Fadel BM, Jaccard A, Linhart A, Mohty D. Comparison of echocardiographic parameters in Fabry cardiomyopathy and light-chain cardiac amyloidosis. Echocardiography. 2018;35(11):1755–63. doi:10.1111/echo.14144. Epub 2018 Sep 24. PMID: 30247786.
  44. Mauhin W, Benveniste O, Amelin D, Montagner C, Lamari  F, Caillaud C, Douillard C, Dussol B, Leguy-Seguin V, D’Halluin P, Noel E, Zenone T, Matignon M, Maillot F, Ly KH, Besson G, Willems M, Labombarda F, Masseau A, Lavigne C, Lidove O. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PloS one. 2020;15(5):e0233460. https://doi.org/10.1371/journal.pone.0233460
  45. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641–59. doi:10.1093/qjmed/hcq117. Epub 2010 Jul 21. PMID: 20660166.
  46. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. doi:10.1001/jama.281.3.249. PMID: 9918480.
  47. Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1):129437. doi:10.1016/j.bbagen.2019.129437. Epub 2019 Sep 14. PMID: 31526868; PMCID: PMC6981246.
  48. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta  A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24(23):2151–5. doi:10.1016/j.ehj.2003.09.017. PMID: 14643276.
  49. Motabar O, Sidransky E, Goldin E, Zheng W. Fabry disease – current treatment and new drug development. Curr Chem Genomics. 2010;23(4):50–6. doi:10.2174/1875397301004010050. PMID: 21127742; PMCID: PMC2995157
  50. Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holz­­mei­­­ster J, Lüscher TF, Jenni R, Duru F. Electrocardiogra­­phic changes in early recognition of Fabry disease. Heart. 2011;97(6):485–90. doi:10.1136/hrt.2010.211789. Epub 2011 Jan 26. PMID: 21270075.
  51. National Fabry Disease Foundation. https://www.fabrydisease.org/index.php/component/content/article?id=130.
  52. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy bet­­ween female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601. doi:10.1016/j.jcmg.2011.01.020. PMID: 21679893.
  53. Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, Störk S, Voelker W, Ertl G, Wanner C, Weidemann F. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol. 2011;37(1):37–43. doi:10.1016/j.ultrasmedbio.2010.10.017. Epub 2010 Nov 16. PMID: 21084151.
  54. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Got­­­tes­­­man  MM, Brady RO, Kulkarni AB. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA. 1997;94(6):2540–4. doi:10.1073/pnas.94.6.2540. PMID: 9122231; PMCID: PMC20124.
  55. Oliveira JP, Nowak A, Barbey F, Torres M, Nunes JP, Teixeira-E-Costa F, Carvalho F, Sampaio S, Tavares I, Pereira O, Soares AL, Carmona C, Cardoso MT, Jurca-Simina IE, Spada M, Ferreira S, Germain DP. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males. Eur J Med Genet. 2020;63(2):103703. doi:10.1016/j.ejmg.2019.103703. Epub 2019 Jun 11. PMID: 31200018.
  56. O’Mahony C, Coats C, Cardona M, Garcia A, Calcag­­­ni-no M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13(12):1781–8. doi:10.1093/europace/eur267. Epub 2011 Aug 18. PMID: 21856674.
  57. Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB; FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331–7. doi:10.1111/j.1365-2133.2007.08002.x. Epub 2007 Jun 15. PMID: 17573884.
  58. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25(3):769–75. doi:10.1093/ndt/gfp554. Epub 2009 Oct 21. PMID: 19846394.
  59. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer  M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–27. doi:10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28. PMID: 29530533.
  60. Palecek T, Dostalova G, Kuchynka P, Karetova D, Bultas  J, Elleder  M, Linhart A. Right ventricular involvement in Fabry disease. J Am Soc Echocardiogr. 2008;21(11):1265–8. doi:10.1016/j.echo.2008.09.002. Epub 2008 Oct 4. PMID: 18835697.
  61. Patel V, O’Mahony C, Hughes D, Rahman MS, Coats C, Murphy  E, Lachmann R, Mehta A, Elliott PM. Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease. Heart. 2015;101(12):961–6. doi:10.1136/heartjnl-2014-306782. Epub 2015 Feb 5. PMID: 25655062.
  62. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. doi:10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18. PMID: 25406305.
  63. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. doi:10.1093/eurheartj/ehw106. Epub 2016 May 23. PMID: 27222591; PMCID: PMC4986030.
  64. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29. PMID: 26320108.
  65. Regenbogen C, Braunisch MC, Schmaderer C, Heemann U. Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review. Cardiovasc Diagn Ther. 2021;11(2):661–71. doi:10.21037/cdt-20-845. PMID: 33968643; PMCID: PMC8102250.
  66. Reuser AJ, Verheijen FW, Bali D, van Diggelen OP, Germain DP, Hwu WL, Lukacs Z, Mühl A, Olivova P, Piraud M, Wuyts B, Zhang K, Keutzer J. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders-current status and perspectives. Mol Genet Metab. 2011;104(1–2):144–8. doi:10.1016/j.ymgme.2011.07.014. Epub 2011 Jul 23. PMID: 21831684.
  67. Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2008;10(5):507–13. doi:10.1016/j.ejheart.2008.03.006. Epub 2008 Apr 10. PMID: 18406204.
  68. Rozenfeld P, Neumann PM. Treatment of fabry disease: current and emerging strategies. Curr Pharm Biotechnol. 2011;12(6):916–22. doi:10.2174/138920111795542705. PMID: 21235448.
  69. Satoh K. Globotriaosylceramide induces endothelial dysfunction in Fabry disease. Arteriosclerosis, Thrombosis, and Vascular Biol. 2014;34:2–4. https://doi.org/10.1161/ATVBAHA.113.
  70. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96(6):842–6. doi:10.1016/j.amjcard.2005.05.033. PMID: 16169374.
  71. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–8. doi:10.1016/j.ymgme.2008.06.016. Epub 2008 Aug 15. PMID: 18707907; PMCID: PMC2593623.
  72. Silva CAB, Moura-Neto JA, Dos Reis MA, Vieira Neto OM, Barreto FC. Renal manifestations of Fabry disease: A Narrative Review. Can J Kidney Health Dis. 2021;8:2054358120985627. doi:10.1177/2054358120985 627. PMID: 33786192; PMCID: PMC7960898.
  73. Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West  ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400–8. doi:10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20. PMID: 25442977.
  74. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Nino-miya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51(1):50–9. doi:10.1016/j.jjcc.2007.12.001. Epub 2008 Feb 6. PMID: 18522775.
  75. Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1–9. doi:10.1136/jmedgenet-2013-101857. Epub 2013 Aug 6. PMID: 23922385.
  76. Van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Lange­­veld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43(5):908–21. doi:10.1002/jimd.12228. Epub 2020 Mar 2. PMID: 32083331; PMCID: PMC7540041.
  77. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–41. doi:10.1111/joim.12077. Epub 2013 May 6. PMID: 23586858; PMCID: PMC4282332.
  78. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP; Fabry Registry. Fema­­les with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112–28. doi:10.1016/j.ymgme.2007.09.013. Epub 2007 Nov 26. PMID: 18037317.
  79. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banika­­zemi M, Packman S, Sims K, Solomon SD. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010;31(9):1088–97. doi:10.1093/eurheartj/ehp588. Epub 2010 Jan 7. PMID: 20061327; PMCID: PMC2912636
  80. Yogasundaram H, Hung W, Paterson ID, Sergi C, Oudit GY. Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. ESC Heart Fail. 2018;5(3):372–5. doi:10.1002/ehf2.12276. Epub 2018 Feb 20. PMID: 29460476; PMCID: PMC5933951.
  81. Zemánek D, Marek J, Dostálová G, Magage S, Roblová L, Kovárník T, Linhart A. Usefulness of alcohol septal ablation in the left ventricular outflow tract obstruction in Fabry disease cardiomyopathy. Am J Cardiol. 2021;150:110–3. doi:10.1016/j.amjcard.2021.03.042. Epub 2021 May 16. PMID: 34011439.
[PDF] [Contents]  

 

 

Right ventricular myocardial infarction

Yu.V. Savitska, A.I. Klantsa, N.V. Shchepina

References

  1. Коваленко В.М., Сичов О.С., Долженко М.М. та ін. Ехокардіографічна оцінка правих відділів серця у дорослих. Рекомендації // WebCardio.org [Internet]. 2016. URL: https://www.webcardio.org/ekhokardioghrafichna-otsinka-pravykh-viddiliv-sertsya-u-doroslykh-rekomendatsiji.aspx.
  2. Стаднік С.М. ЕКГ-діагностика інфаркту міокарда правого шлуночка. Медицина неотложных состояний. 2013. № 3(50). С. 69–71. URL: https://cyberleninka.ru/article/n/ekg-diagnostika-infarkta-miokarda-pravogo-zheludochka/viewer.
  3. Стаднік С.М. Інфаркт міокарда правого шлуночка: проблеми діагностики. Здоров’я України. 2013. № 8. С. 66–67. URL: https://health-ua.com/pics/pdf/ZU_2013_Cardio_2/66-67.pdf
  4. Jeffers J, Boyd K, Parks L. Right ventricular myocardial infarction // StatPearls Publishing [Internet]. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/28613702/
  5. Lupi-Herrera E, González-Pacheco H, Juárez-Herrera U, et al. Primary reperfusion in acute right ventricular infarction: An observational study. World J Cardiol. 2014;6(1):14–22. URL: https://pubmed.ncbi.nlm.nih.gov/24527184/
  6. Venkatachalam S, Wu G, Ahmad M. Echocardiographic assessment of the right ventricle in the current era: Application in clinical practice. Echocardio­­­graphy. 2017;34(12):1930–47. URL: https://pubmed.ncbi.nlm.nih.gov/28833543/
[PDF] [Contents]  

 

Dreaded coronary artery perforations during percutaneous coronary artery interventions

H.C. Ramesh, R. Varadaraju, M. Chandrasena, P.K. Sunil, A. Cherukumudi

References

  1. Al-Lamee AR, Ielasi A, Latib A, et al. Incidence, predictors, management, immediate and long-term outcomes following grade III coronary perforation. JACC Cardiovasc Interv. 2011;4:87e95.
  2. Celiento M, Scioti G, Pratali S, et al. Repair of coronary artery perforation following angioplasty using TachoSil patches. Interactive Cardio Vascular and Thorac Surg. 2010;10:328–30.
  3. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era: incidence, classification, management, and outcome. Circulation. 1994;90:2725–30.
  4. Fukui T, Takanashi S, Mihara W, et al. Coronary endarterectomy and stent removal after iatrogenic perforation. Ann Thorac Surg. 2004;77(2):708–11. DOI:10.1016/S0003-4975(03)01424-3.
  5. Gasparini GL, Merella P, Mazzarotto P, Gagnor A, Garbo R, et al. Retrograde approach-related epicardial collateral channel perforation successfully treated with simultaneous bilateral coils embolization: a case illustration and review. Cardiovasc Revasc Med. 2018;19:879–86.
  6. Inoue Y, Ueda T, Taguchi S, et al. Teflon Felt Wrapping Repair for Coronary Perforation After Failed Angioplasty. Ann Thorac Surg. 2006;82:2312–4.
  7. Krishnegowda C, Puttegowda B, Krishnappa S, et al. Incidence, clinical and angiographic characteristics, management and outcomes of coronary artery perforation at a high volume cardiac care center during percutaneous coronary intervention. Indian Heart J. 2020;72(4):232–8. https://doi.org/10.1016/j.ihj.2020.07.012.
  8. Lemmert ME, Bommel RJ, Diletti R, et al. Clinical characteristics and management of coronary artery perforations: a single-center 11-year experience and practical overview. J Am Heart Assoc. 2017;6:e007049.
  9. Loubeyre C, Morice M-C, Berzin B, et al. Emergency coronary artery bypass surgery following coronary angioplasty and stenting. Results of a French multicenter registry. Catheter Cardiovasc Interv. 1999;48:441–8.
  10. Shimony A, Zahger D, Van Straten M, et al. Incidence, risk factors, management and outcomes of coronary artery perforation during percutaneous coronary intervention. Am J Cardiol. 2009;104:1674–7.
  11. Szczechowicz MP, Mkalaluh S, Torabi S, et al. Bailout bypass surgery for complications of coronary interventions. Asian Cardiovascular & Thorac Ann. 2020;28(4):205–12. DOI:10.1177/0218492320919200.
  12. Trana C, Muller O, Roguelov C, et al. Deciding on the best course of action for grade III coronary perforations. Interv Cardiol. 2011;3(3):321–7.
  13. Tumscitz C, Lanzillotti V, Pirani L, Di Cesare AM, Scoccia A, Gallo F. Type III coronary perforation during chronic total occlusion percutaneous coronary interventions treated with Cyanoacrylate glue embolization: case report and review of the technique. Vessel Plus. 2019;3:20.
  14. Verevkin A, Aspern K, Leontyev S, Lehmann S, et al. Early and Long-Term Outcomes in Patients Undergoing Cardiac Surgery Following Iatrogenic Injuries during Percutaneous Coronary Intervention. J Am Heart Assoc. 2019;8:e010940. DOI:10.1161/JAHA.118.010940.

 

[PDF] [Contents]  

 

2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines

J.S. Lawton, J.E. Tamis-Holland, S. Bangalore, E.R. Bates, T.M. Beckie, J.M. Bischoff, J.A. Bittl, M.G. Cohen, J.M. DiMaio, C.W. Don, S.E. Fremes, M.F. Gaudino, Z.D. Goldberger, M.C. Grant, J.B. Jaswal, P.A. Kurlansky, R. Mehran, T.S. Metkus Jr, L.C. Nnacheta, S.V. Rao, F.W. Sellke, G. Sharma, C.M. Yong, B.A. Zwischenbergeri

References

 

Complete list of references

 

[PDF] [Contents]

Crossref Member Badge

© "Cardiac Surgery and Interventional Cardiology" Ukrainian scientific and practical peer-reviewed journal, 2023

slot demo pg